Skip to main content

CORRECTION article

Front. Pharmacol., 16 July 2020
Sec. Pharmacology of Anti-Cancer Drugs
Volume 11 - 2020 | https://doi.org/10.3389/fphar.2020.01088

Corrigendum: Shikonin Inhibits Cancer Through P21 Upregulation and Apoptosis Induction

This article is a correction to:

  1. Shikonin Inhibits Cancer Through P21 Upregulation and Apoptosis Induction

    1. Read original article
Fangfang Wang,Fangfang Wang1,2Franklin Mayca PozoFranklin Mayca Pozo3Danmei Tian,Danmei Tian1,2Xinran GengXinran Geng3Xinsheng Yao,*Xinsheng Yao1,2*Youwei Zhang*Youwei Zhang3*Jinshan Tang,*Jinshan Tang1,2*
  • 1Institute of Traditional Chinese Medicine and Natural Products, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drug Research, College of Pharmacy, Jinan University, Guangzhou, China
  • 2International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), College of Pharmacy, Jinan University, Guangzhou, China
  • 3Department of Pharmacology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States

A Corrigendum on
Shikonin Inhibits Cancer Through P21 Upregulation and Apoptosis Induction

by Wang F, Pozo FM. Tian D, Geng X, Yao X, Zhang Y and Tang J (2020) Shikonin Inhibits Cancer Through P21 Upregulation and Apoptosis Induction. Front. Pharmacol. 11:861. doi: 10.3389/fphar.2020.00861

In the published article, there was an error regarding the contribution of “Xinsheng Yao,” who should be a co-corresponding author.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: Shikonin, anticancer effect, cell cycle arrest, autophagy, apoptosis, P21

Citation: Wang F, Mayca Pozo F, Tian D, Geng X, Yao X, Zhang Y and Tang J (2020) Corrigendum: Shikonin Inhibits Cancer Through P21 Upregulation and Apoptosis Induction. Front. Pharmacol. 11:1088. doi: 10.3389/fphar.2020.01088

Received: 29 June 2020; Accepted: 03 July 2020;
Published: 16 July 2020.

Copyright © 2020 Wang, Mayca Pozo, Tian, Geng, Yao, Zhang and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xinsheng Yao, tyaoxs@jnu.edu.cn; Youwei Zhang, yxz169@case.edu; Jinshan Tang, gztangjinshan@126.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.